GKOS vs BIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 24, 2026

GKOS

39.5
AI Score
VS
BIO Wins

BIO

63.9
AI Score

Investment Advisor Scores

GKOS

40score
Recommendation
AVOID NEW MONEY

BIO

64score
Recommendation
STRONG BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric GKOS BIO Winner
Forward P/E 1666.6667 41.3223 BIO
PEG Ratio 1.64 1.1905 BIO
Revenue Growth 49.5% -0.1% GKOS
Earnings Growth 1896.3% 18.7% GKOS
Tradestie Score 39.5/100 63.9/100 BIO
Profit Margin -30.7% 8.6% BIO
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY STRONG BUY BIO

Relative Price Performance (Last 90 Days)

GKOS 1M: +15.5% · 3M: +17.8% BIO 1M: -4.5% · 3M: +16.9%

Current Technical Phase

GKOS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 63

RSI (14): 62.7 · Price: $178.88

BIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 53

RSI (14): 53.2 · Price: $369.95

Fundamentals Snapshot

Metric GKOS BIO
Market Cap — —
Forward P/E 342.2 38.0
Trailing P/E — 45.7
Revenue (TTM) — —
Revenue Growth 0.5% 0.0%
Gross Margin 0.8% 0.5%
Operating Margin -0.1% 0.1%
EPS -3.26 7.96
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, BIO is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.